---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-252054"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:28:22.565407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno Therapeutics Q3 net loss $76.6M; NDA for DCCR in PWS accepted with Priority Review, PDUFA Dec 27, 2024

## Summary
- NDA for DCCR (diazoxide choline) for Prader-Willi syndrome accepted by FDA with Priority Review; PDUFA target action date December 27, 2024.
- Net loss $76.6M ($1.83/sh) vs $10.9M ($0.95/sh) in Q3 2023; increase driven by non-cash stock-based compensation tied to NDA milestones.
- R&D expense $30.1M (includes $18.5M stock comp); G&A expense $49.2M (includes $38.1M stock comp), both up significantly from prior year.
- Cash, cash equivalents and marketable securities $284.7M as of Sept 30, 2024; cash used in operations $14.9M in Q3.
- Board appointed Dawn Carter Bir and Matthew Pauls assumed Lead Independent Director role.

## SEC filing metadata
- accession: 0001193125-24-252054
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312524252054/0001193125-24-252054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312524252054/d889134d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-252054
- JSON: https://secwatch.observer/filing/0001193125-24-252054.json
- Plain text: https://secwatch.observer/filing/0001193125-24-252054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.